clinical trials, neuroscience

Researchers caution that it’s too soon to recommend supplements based on the results of a new study.

The group’s 7-2 ruling in favor of the therapeutic represents a shift from previous deliberations, in which data on its effectiveness was deemed insufficient.

The country’s provisional go-ahead could increase pressure already being exerted on the US Food and Drug Administration to approve the therapy.

Testing in animals and lab-grown cells suggests the experimental drug could enhance the function of lysosomes within cells.

Some experts argue that better trials are needed before putting interventions into practice.

Researchers say they hope to launch a clinical trial to test bumetanide, a diuretic approved in 2002, but how it might improve neural functioning is unclear.

The FDA pauses the research program on a lentivirus-based treatment for a rare neurological condition after a patient developed a bone marrow disorder that could presage leukemia.

After receiving an intraocular injection of the gene for a light-sensitive protein, a 58-year-old man diagnosed with the neurodegenerative eye disease retinitis pigmentosa was able to locate objects on a table using engineered goggles.

Patients who received the drug fared better cognitively and functionally than those taking placebo, but still experienced losses in performance.

Two out of three people who received noninvasive ultrasound appear to have gained some level of consciousness, according to preliminary trial results.

The world was rocked by the COVID-19 pandemic this year, but researchers rose to all manner of challenges.

The University of Alabama at Birmingham neuroscientist aims to determine which cells are most important in prompting the disease’s initiation and progression.

After six months, patients with fast-progressing amyotrophic lateral sclerosis who had received the experimental treatment had less loss of function than those who received a placebo.

A look at some of the circulating molecules that may indicate various Alzheimer’s pathologies and serve as the bases of noninvasive tests for the disease.

Researchers hope circulating biomarkers will enable earlier detection and better monitoring of the neurodegenerative disorder—and perhaps help usher in new treatments.

Several early-stage clinical trials indicate that implanting patients with the cells is safe. But whether they can alleviate neurological problems remains to be seen.

Epidiolex, a cannabis-derived medicine for epilepsy, will prompt federal regulatory changes that could crack open access to study the plant.

A Phase 1 clinical trial shows the noninvasive technique is safe and could aid in the delivery treatments to the brain.